mRNA Synthesis Raw Materials Market (By Type: Capping analogs, nucleotides; By Application; By End-user) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

mRNA is synthesized in the nucleus with the use of a template made up of a DNA nucleotide sequence. This process is referred to as transcription. It involves various stages such as initiation, elongation, editing, and termination. The raw materials required are bacteriophage, DNA template, RNA polymerase, and NTPs. The amino acids required for transcription are uracil, cytosine, adenine, and guanine. Following are the steps of mRNA synthesis:

  • Designing target gene and production of plasmid
  • Purification and linearization of the plasmid
  • mRNA synthesis
  • mRNA purification
  • mRNA analytics
  • Final formulation 

mRNA synthesis has a wide range of applications in the manufacturing of therapeutics, vaccine development, and drug discovery. RNA–based vaccines have higher efficiency, better immunogenicity, and require short production time. Moreover, the manufacturing cost of the synthesis is also low. For instance, in November 2020, Pfizer, Inc. and BioNtech, Inc. launched a vaccine BNT162b2 against the SARS-CoV-2 COVID-19 virus. The advancements in medical technologies propel the market. Along with this, improvement in the service quality through novel product launches by the major pharmaceutical companies drives the RNA synthesis raw material market. 

The demand for gene therapies has increased due to the increasing prevalence of cancer and chronic diseases. The rise in awareness among people and healthcare workers for the early diagnosis and treatment of chronic disorders has also increased. Due to the approach of delivering products with better quality and efficacy, the key players in the market have a higher demand for quality raw materials for efficient mRNA synthesis. This is required for developing efficient and safe drug products, vaccines, and therapeutics. Moreover, the collaborations, mergers and strategic alliances between the key players to enhance the raw material supply propels the market. For instance, in September 2022, TriLink Bio Technologies announced its expansion in delivering the GMP-grade product N1-Methyl Pseudouridine-5'-Triphosphate. It is the modified form of the NTP required for the synthesis of mRNA. This new product launch enhances the company's GMP capabilities and analytical testing department.

The market is segmented into type, application, end-use, and region. The type segment is divided into capping analogs, DNA template, nucleotides and polymerase. The application segment is classified into therapeutic production, vaccine production, and drug discovery. The end user segment is classified into biotechnology companies, pharmaceutical companies, research and academic institutes, and others. The region segment is classified into North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa. 

Based on the regional analysis, North America dominates the global mRNA synthesis raw materials market. The availability of the key market players for the supply of raw materials and increased research funding drives the market. Moreover, North America also has a large number of clinical trial activities which boosts the growing market. Europe also holds a significant stake due to the increasing need and awareness for mRNA-based vaccines and therapeutics for treating chronic and genetic disorders. 

Major companies operating in the mRNA synthesis raw materials market include Thermo Fisher Scientific, Inc., Jena Bioscience, Sartorius AG, Cytiva, Moderna, Inc., H3 Biomedicine Inc., Kernal Biologics, Ziphius Therapeutics, Merck KGaA, miRagen Therapeutics, Inc., Skyhawk Therapeutics, Inc., Tiba Biotechnology, CureVac, Translate Bio, Sigma Aldrich, TriLink Bio Technologies among others.

Market Segmentation

By Type

  • Capping Enzymes
  • DNA template
  • Nucleotides
  • Polymerase

By Application

  • Therapeutics Production,
  • Vaccine Production,
  • Drug Discovery

By End-user

  • Biotechnology Companies,
  • Pharmaceutical Companies,
  • Research and Academic Institutes,
  • Others

By Region

  • North America 
  • Europe 
  • Asia-Pacific 
  • Latin America 
  • Middle East And Africa

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on MRNA Synthesis Raw Materials Market 

5.1. COVID-19 Landscape: MRNA Synthesis Raw Materials Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global MRNA Synthesis Raw Materials Market, By Type

8.1. MRNA Synthesis Raw Materials Market, by Type, 2022-2030

8.1.1 Capping Enzymes

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. DNA template

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Nucleotides

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Polymerase

8.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global MRNA Synthesis Raw Materials Market, By Application

9.1. MRNA Synthesis Raw Materials Market, by Application, 2022-2030

9.1.1. Therapeutics Production

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Vaccine Production

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Drug Discovery

9.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global MRNA Synthesis Raw Materials Market, By End-user 

10.1. MRNA Synthesis Raw Materials Market, by End-user, 2022-2030

10.1.1. Biotechnology Companies

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Pharmaceutical Companies

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Research and Academic Institutes

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global MRNA Synthesis Raw Materials Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Type (2017-2030)

11.1.2. Market Revenue and Forecast, by Application (2017-2030)

11.1.3. Market Revenue and Forecast, by End-user (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.1.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.1.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.1.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.1.5.3. Market Revenue and Forecast, by End-user (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.3. Market Revenue and Forecast, by End-user (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.5.3. Market Revenue and Forecast, by End-user (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.6.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.6.3. Market Revenue and Forecast, by End-user (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.7.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.7.3. Market Revenue and Forecast, by End-user (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.3. Market Revenue and Forecast, by End-user (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.5.3. Market Revenue and Forecast, by End-user (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.6.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.6.3. Market Revenue and Forecast, by End-user (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.7.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.7.3. Market Revenue and Forecast, by End-user (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.5.3. Market Revenue and Forecast, by End-user (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.6.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.6.3. Market Revenue and Forecast, by End-user (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.7.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.7.3. Market Revenue and Forecast, by End-user (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.5.3. Market Revenue and Forecast, by End-user (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.5.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.5.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.5.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.5.5.3. Market Revenue and Forecast, by End-user (2017-2030)

Chapter 12. Company Profiles

12.1. Thermo Fisher Scientific, Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Jena Bioscience

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Sartorius AG

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Cytiva

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Moderna, Inc.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. H3 Biomedicine Inc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Kernal Biologics

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Ziphius Therapeutics

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Merck KGaA

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. miRagen Therapeutics, Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers